The amplification of the epidermal growth factor (EGF) receptor (EGFR), HER2, as well as PRLR in breast cancers, has been regarded to accelerate tumor growth by activating their downstream signaling pathways [23]. This evidence concerns the gene ERBB2 and neoplasm.